Limits...
9α,11β-PGF2, a Prostaglandin D2 Metabolite, as a Marker of Mast Cell Activation in Bee Venom-Allergic Patients.

Nittner-Marszalska M, Cichocka-Jarosz E, Sanak M, Wujczyk M, Dor-Wojnarowska A, Lis G, Liebhart J - Arch. Immunol. Ther. Exp. (Warsz.) (2015)

Bottom Line: Allergen challenge resulted in a significant increase of 9α,11β-PGF2 levels between 5 and 15 min after provocation only in BVA patients (p < 0.05).Skin chamber seems to be a promising, non-invasive and safe model of in vivo allergen provocation in BV-allergic patients.High or low levels of both mediators do not predict occurrence of adverse events during VIT.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Diseases, Geriatrics and Allergology Medical University, Wroclaw, Poland, marmarsz@gmail.com.

ABSTRACT
Mast cell (MC) mediators, among them prostaglandin D2 (PGD2) and 9α,11β-PGF2, PGD2's metabolite, play a key role in allergic reactions, including bee venom anaphylaxis (BVA). Assessment of these mediators has never been performed in BVA. The aim of the study was to assess the activation of MC during in vivo provocation with bee venom (BV) and to measure PGD2 and 9α,11β-PGF2 in the course of an allergen challenge. The second aim was to determine if assessment of these mediators could be useful for predicting adverse events during venom immunotherapy (VIT). In 16 BV-VIT patients and 12 healthy subjects, levels of PGD2 and 9α,11β-PGF2 were assessed during BV provocation by means of the skin chamber method. Chamber fluids, collected at 5 and 15 min, were analyzed for both mediators by gas chromatography mass spectrometry negative ion chemical ionization. BVA in comparison to non-allergic patients had a significantly higher ratio of 9α,11β-PGF2 in allergen-challenged chambers to 9α,11β-PGF2 in allergen-free chambers after 15 min of provocation (p = 0.039). Allergen challenge resulted in a significant increase of 9α,11β-PGF2 levels between 5 and 15 min after provocation only in BVA patients (p < 0.05). Analysis of log-transformed PGD2 levels showed significant difference between changes in PGD2 concentration between BVA and healthy subjects. No study patient developed adverse reactions during. 9α,11β-PGF2 is actively generated during the early allergic response to BV. Skin chamber seems to be a promising, non-invasive and safe model of in vivo allergen provocation in BV-allergic patients. High or low levels of both mediators do not predict occurrence of adverse events during VIT.

No MeSH data available.


Related in: MedlinePlus

ROC curve for ratio of 9α,11β-PGF2 concentration between 15th and 5th minute in allergen-challenged chamber
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4499103&req=5

Fig3: ROC curve for ratio of 9α,11β-PGF2 concentration between 15th and 5th minute in allergen-challenged chamber

Mentions: To evaluate usefulness of 9α,11β-PGF2 and PGD2 ratios after allergen extract provocation in discrimination between allergic and control group ROC curve was applied (Fig. 3). Only a parameter calculated as fold change (ratio) of 9α,11β-PGF2 concentration between 15th and 5th minute in allergen-challenged chamber revealed a significant area under ROC curve (AUC = 0.74; p = 0.019). For the ratio equal to 1.62, the optimal sensitivity (equal 71.4 %) and specificity (equal 83.3 %) were observed.Fig. 3


9α,11β-PGF2, a Prostaglandin D2 Metabolite, as a Marker of Mast Cell Activation in Bee Venom-Allergic Patients.

Nittner-Marszalska M, Cichocka-Jarosz E, Sanak M, Wujczyk M, Dor-Wojnarowska A, Lis G, Liebhart J - Arch. Immunol. Ther. Exp. (Warsz.) (2015)

ROC curve for ratio of 9α,11β-PGF2 concentration between 15th and 5th minute in allergen-challenged chamber
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4499103&req=5

Fig3: ROC curve for ratio of 9α,11β-PGF2 concentration between 15th and 5th minute in allergen-challenged chamber
Mentions: To evaluate usefulness of 9α,11β-PGF2 and PGD2 ratios after allergen extract provocation in discrimination between allergic and control group ROC curve was applied (Fig. 3). Only a parameter calculated as fold change (ratio) of 9α,11β-PGF2 concentration between 15th and 5th minute in allergen-challenged chamber revealed a significant area under ROC curve (AUC = 0.74; p = 0.019). For the ratio equal to 1.62, the optimal sensitivity (equal 71.4 %) and specificity (equal 83.3 %) were observed.Fig. 3

Bottom Line: Allergen challenge resulted in a significant increase of 9α,11β-PGF2 levels between 5 and 15 min after provocation only in BVA patients (p < 0.05).Skin chamber seems to be a promising, non-invasive and safe model of in vivo allergen provocation in BV-allergic patients.High or low levels of both mediators do not predict occurrence of adverse events during VIT.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Diseases, Geriatrics and Allergology Medical University, Wroclaw, Poland, marmarsz@gmail.com.

ABSTRACT
Mast cell (MC) mediators, among them prostaglandin D2 (PGD2) and 9α,11β-PGF2, PGD2's metabolite, play a key role in allergic reactions, including bee venom anaphylaxis (BVA). Assessment of these mediators has never been performed in BVA. The aim of the study was to assess the activation of MC during in vivo provocation with bee venom (BV) and to measure PGD2 and 9α,11β-PGF2 in the course of an allergen challenge. The second aim was to determine if assessment of these mediators could be useful for predicting adverse events during venom immunotherapy (VIT). In 16 BV-VIT patients and 12 healthy subjects, levels of PGD2 and 9α,11β-PGF2 were assessed during BV provocation by means of the skin chamber method. Chamber fluids, collected at 5 and 15 min, were analyzed for both mediators by gas chromatography mass spectrometry negative ion chemical ionization. BVA in comparison to non-allergic patients had a significantly higher ratio of 9α,11β-PGF2 in allergen-challenged chambers to 9α,11β-PGF2 in allergen-free chambers after 15 min of provocation (p = 0.039). Allergen challenge resulted in a significant increase of 9α,11β-PGF2 levels between 5 and 15 min after provocation only in BVA patients (p < 0.05). Analysis of log-transformed PGD2 levels showed significant difference between changes in PGD2 concentration between BVA and healthy subjects. No study patient developed adverse reactions during. 9α,11β-PGF2 is actively generated during the early allergic response to BV. Skin chamber seems to be a promising, non-invasive and safe model of in vivo allergen provocation in BV-allergic patients. High or low levels of both mediators do not predict occurrence of adverse events during VIT.

No MeSH data available.


Related in: MedlinePlus